Verona Investors Gasp As Lead Asset Misses Main Endpoint In COPD Trial
Executive Summary
Verona’s shares sank after a brief three-day Phase II trial using lead asset RPL554 in patients already maximally bronchodilated on both a LAMA and LABA missed the primary endpoint.